NICE wants more RoActemra data in JIA

The U.K.'s NICE said it needs additional information before it can recommend the use of RoActemra tocilizumab from Roche (SIX:ROG; OTCQX:RHHBY) to treat systemic juvenile idiopathic arthritis in patients who have responded inadequately to NSAIDs, systemic corticosteroids and methotrexate. The agency asked for data comparing RoActemra to other drugs used to treat the disease, data about long-term joint damage and a revised economic model. NICE did say it will not recommend RoActemra for patients who have yet to receive methotrexate, but have received NSAIDs and systemic corticosteroids. Comments are due by Sept. 1. ...